Ownership Capital B.V. Has $8.50 Million Stock Holdings in Zoetis Inc. $ZTS

Ownership Capital B.V. decreased its position in Zoetis Inc. (NYSE:ZTS) by 89.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 58,099 shares of the company’s stock after selling 485,480 shares during the period. Zoetis makes up 4.8% of Ownership Capital B.V.’s portfolio, making the stock its 11th largest position. Ownership Capital B.V.’s holdings in Zoetis were worth $8,501,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Patton Fund Management Inc. acquired a new position in shares of Zoetis in the 2nd quarter valued at approximately $224,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.1%

NYSE ZTS opened at $123.89 on Tuesday. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock has a 50 day moving average of $123.68 and a 200-day moving average of $137.91. The company has a market cap of $54.60 billion, a PE ratio of 20.86, a PEG ratio of 2.15 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Morgan Stanley set a $160.00 price target on Zoetis in a research note on Thursday, December 18th. Bank of America cut Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research report on Monday, December 15th. Piper Sandler reissued a “neutral” rating and issued a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research report on Thursday. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.